+

WO2009112800A1 - Losartan composition - Google Patents

Losartan composition Download PDF

Info

Publication number
WO2009112800A1
WO2009112800A1 PCT/GB2009/000531 GB2009000531W WO2009112800A1 WO 2009112800 A1 WO2009112800 A1 WO 2009112800A1 GB 2009000531 W GB2009000531 W GB 2009000531W WO 2009112800 A1 WO2009112800 A1 WO 2009112800A1
Authority
WO
WIPO (PCT)
Prior art keywords
losartan
composition according
composition
agents
suspension
Prior art date
Application number
PCT/GB2009/000531
Other languages
French (fr)
Inventor
Carl David Tiernery
Original Assignee
Rosemont Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosemont Pharmaceuticals Ltd filed Critical Rosemont Pharmaceuticals Ltd
Publication of WO2009112800A1 publication Critical patent/WO2009112800A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to a losartan composition, a method of use thereof and a method of manufacture.
  • Losartan is an active agent which is metabolised by cytochrome P450 enzymes in the human body to form an active carboxylic acid metabolite that is responsible for angiotension II receptor antagonism. Losartan containing drugs are therefore often used to treat high blood pressure.
  • the systemic name for losartan is [2-butyl-4-chloro- l -( ⁇ 4- [2-(2H- l ,2,3,4-tetrazol-5- yl)phenyl]phenyl ⁇ methyl) -lH-imidazol-5-yl] -methanol or
  • Losartan potassium a pharmaceutically acceptable salt of losartan
  • a solid dosage form which can be difficult for some patient's to swallow, or a liquid solution form as disclosed in WO2007016352.
  • the losartan in the liquid solution form is typically completely dissolved in an aqueous solution to form a particle free solution.
  • losartan solutions a problem with known losartan solutions is that the losartan tends to degrade over time to form dimer degradation products.
  • losartan potassium has a bitter taste which is difficult to mask even with strong flavourings or sweetening agents.
  • a further aim of the present invention to provide a method of manufacturing an improved losartan composition for oral administration.
  • a losartan composition suitable for oral administration said composition containing a pharmaceutically acceptable salt of losartan and a carrier agent, the losartan salt forming a suspension with said carrier agent.
  • the losartan suspension formed has a significantly improved flavour and the bitter taste is significantly reduced.
  • the suspension is substantially more stable than losartan solutions .
  • the term "suspension” used herein is where the losartan salt is substantially homogenously dispersed or “suspended" in the carrier agent. This is contrasted with prior art losartan “solutions” wherein the losartan salt is substantially dissolved in a carrier agent.
  • Any suitable salt of losartan can be used for the losartan suspension.
  • the pharmaceutically acceptable salt of losartan used is losartan potassium.
  • the pH of the composition is less than 7.
  • the carrier agent is at a pH of less than 7.
  • one or more pH modifying or buffering agents can be included in the composition with the carrier agent to adjust and/or maintain the pH below 7 and to an optimum pH value.
  • the acidic pH of the final composition reduces the solubility of the losartan in the carrier agent, thereby forming the suspension.
  • the one or more pH modifying agents can include any or any combination of citric acid, sodium citrate, disodium hydrogen phosphate, sodium dihydrogen phosphate and/or the like.
  • the pH modifying agents are used in such suitable amounts to provide the composition with an optimum pH.
  • Preferably the one or more pH modifying agents are provided at a concentration of 7mmol. Further preferably the concentration of the one or more pH modifying agents is between 70-90mmol. Most preferably the concentration of the pH modifying agent is 90mmol.
  • the pH range of the final suspension is between 2-6, further preferably the pH range is 3.5-6 and yet further preferably the pH range is 3.5-4.5. In a preferred embodiment the pH of the final suspension is pH 4.0.
  • a wetting agent is included in the composition to aid dispersion of the losartan salt. This is preferable if the pH of the final suspension is 3 or below since at this pH the losartan salt can be difficult to disperse to form a substantially homogenous suspension.
  • wetting agents examples include a sorbiton fatty ester, such as for example Tween 80 (polysorbate 80) .
  • Tween 80 polysorbate 80
  • Other surfactants or combinations of surfactants could also be used.
  • an anti-foaming agent is included in the composition to minimise the amount of foam produced during manufacture of the composition.
  • the anti-foaming agent preferably includes a silicon based agent, such as for example simethicone emulsion
  • one or more suspension agents are provided as the carrier agent or used in addition to the carrier agent.
  • the suspension agent preferably acts to thicken the suspension to prevent settling of the losartan salt from the suspension.
  • the one or more suspension agents include any or any combination of microcrystalline cellulose, carboxymethycellulose, carmellose sodium, Magnesium Aluminium Silicate (Veegum K), Xantham Gum, and/or any alternative salts thereof and/or the like.
  • the Veegum K is used in a larger amount than the other suspension agent or agents.
  • a combination of suspension agents is typically found to reduce the concentration of the agents required in the composition.
  • Preferred combinations include: a) Avicel RC591 (microcrystalline cellulose + carboxymethycellulose) with carmellose sodium; b) Veegum K with carboxymethycellulose sodium; or c) Veegum K with Xantham Gum.
  • an optimum concentration of suspension agents include Veegum K at approximately 0.7%w/v combined with Xanthum Gum at approximately 0.4%w/v. (w/v —weight of the final volume of the composition) .
  • the combination and concentration of the suspension agents chosen typically provide a fluid or liquid pourable suspension which minimises the tendency of losartan to settle out of the suspension.
  • the carrier agent in one embodiment is an aqueous carrier agent, such as for example water or purified water.
  • one or more anti-microbial agents are included in the composition.
  • sodium benzoate can be used at it is effective at the optimum pH of the composition.
  • the anti-microbrial agent could include any or any combination of benzoic acid, methyl hydroxybenzoate, propyl hydroxybenzoate, other analogues of the hydroxybenzoates and/or the like.
  • sweetener agents Preferably one or more sweetener agents, flavouring agents, anti-oxidant agents, preservative agents and/or the like are included in the composition.
  • a pharmaceutically acceptable dosage of the losartan salt is used in the composition.
  • the dosage is 50mg of losartan potassium in a 5ml aqueous solution.
  • a method of manufacturing a losartan composition suitable for oral administration including the steps of mixing a pharmaceutically acceptable salt of losartan with a suitable carrier agent so that the losartan salt forms a suspension with the carrier agent.
  • the target pH of the composition is less than 7 and, if the composition is not less than 7 or unlikely to be less than 7, one or more pH modifiers are added to the composition before or after said losartan salt.
  • the composition can be mixed together using any suitable mixing means .
  • the components of the composition can be mixed together in any order, although it is preferable that the pH modifiers or buffer components are added before the losartan salt to ensure the losartan remains as a suspension rather than a solution. If the losartan salt is added before the pH modifiers or buffers, it is likely that the losartan salt will dissolve into solution rather than forming a suspension. On subsequent addition of the pH modifiers or buffers, the losartan salt will precipitate out of the solution to form a suspension but the losartan salt may be of a different particle size.
  • the losartan salt is added to the composition in particulate or granular form.
  • the particle size of the losartan potassium used to produce the composition is preferably between 14-150 ⁇ m
  • the method of manufacture takes place at room temperature (i.e. approx 20-25 0 C) and pressure (i.e. approx. 1 bar) .
  • a losartan suspension for the manufacture of a medicament for the treatment of lowering blood pressure in a patient.
  • the patient is preferably a human patient.
  • the present invention provides a pharmaceutically effective, safe and simple to administer oral liquid dosage form that will benefit a patient group that have problems in swallowing.
  • Figure 1 is a graph illustrating the stability of losartan in suspension at different pH values.
  • Each suspension was given a batch number (D454-1/011A, D454-1/011B and D454-1/001C) and was stored in a suitable container at room temperature (25 0 C). Samples were taken at 0, 2, 4, 8 and 12 weeks to determine the %SA (percentage of the stated amount of the single dose in the original sample of 50mg/5ml of losartan potassium). The results of the stability- test are shown in Figure 1 and Table 2 and Table 3 below:
  • polysorbate 80 as a wetting agent aided the dispersion of the losartan salt in the formulation but was found not to be critical for forming the suspension. In addition, other wetting agents could be used if required. In order to determine the actual amount of the losartan salt present in the suspension, the following assay was undertaken using losartan potassium as the pharmaceutically acceptable salt.
  • Losartan potassium at a concentration of 1.0%w/v (5mg/ 5ml) was added to 90mmol of citrate phosphate buffer solutions at different pH and mixed until dispersed to form a suspension. The samples were then filtered and filtrate was analysed to determine the amount of losartan that had dissolved into solution. The amounts of losartan potassium in solution at the various pH's are shown in Table 4 below.
  • Purified water (A) is added to the main manufacturing vessel.
  • the citric acid monohydrate is added to the main vessel and mixed until dissolved.
  • the sodium dihydrogen phosphate dihydrate is added to the main vessel and mixed until dissolved.
  • the sodium benzoate is added to the main vessel and mixed until dissolved.
  • the Tween 80 is added to the main vessel and mixed until dispersed.
  • the losartan potassium is added to the main vessel and mixed until a homogeneous suspension is produced.
  • the Simethicone emulsion (Q7-2587 30%) is added to the main vessel and mixed until dispersed.
  • Veegum K and xanthan gum are added to a separate container and mixed until a uniform powder mixture is produced.
  • the powder blend produced at stage 8 is slowly added to the main vessel and mixed until dispersed and a homogeneous thickened suspension is produced.
  • the liquid maltitol is added to the main vessel and mixed until dispersed.
  • Acesulfame k is added to the main vessel and mixed until dissolved.
  • the compound orange spirit is added to the main vessel and mixed until dispersed.
  • target pH is 4.0. If the pH is outside the range of 3.8 - 4.2 the pH is adjusted until it is within this range by adding either 10%w/w citric acid monohydrate solution to lower pH or 10%w/w solution of disodium hydrogen phosphate anhydrous to increase the pH.
  • Purified water (B) is then added to make to the final volume and mixed until dispersed.
  • the finished product is filled into amber glass bottles (to reduce any reaction with sunlight) which are closed with suitable closures.
  • Polysorbate 80 (Tween 80) 1.0g
  • Polysorbate 80 (Tween 80) 1.0g

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A losartan composition is provided which is suitable for oral administration. The composition contains a pharmaceutically acceptable salt of losartan and a carrier agent. The losartan salt forms a suspension with the carrier agent.

Description

Losartan composition
This invention relates to a losartan composition, a method of use thereof and a method of manufacture.
Losartan is an active agent which is metabolised by cytochrome P450 enzymes in the human body to form an active carboxylic acid metabolite that is responsible for angiotension II receptor antagonism. Losartan containing drugs are therefore often used to treat high blood pressure. The systemic name for losartan is [2-butyl-4-chloro- l -({4- [2-(2H- l ,2,3,4-tetrazol-5- yl)phenyl]phenyl} methyl) -lH-imidazol-5-yl] -methanol or
C22H23CIN6O.
Losartan potassium, a pharmaceutically acceptable salt of losartan, is generally given to patients in a solid dosage form, which can be difficult for some patient's to swallow, or a liquid solution form as disclosed in WO2007016352. The losartan in the liquid solution form is typically completely dissolved in an aqueous solution to form a particle free solution. However, a problem with known losartan solutions is that the losartan tends to degrade over time to form dimer degradation products. In addition, losartan potassium has a bitter taste which is difficult to mask even with strong flavourings or sweetening agents.
It is therefore an aim of the present invention to provide an improved losartan composition that can be administered orally and which overcomes the abovementioned problems.
It is a further aim of the present invention to provide a method of manufacturing an improved losartan composition for oral administration. According to a first aspect of the present invention there is provided a losartan composition suitable for oral administration, said composition containing a pharmaceutically acceptable salt of losartan and a carrier agent, the losartan salt forming a suspension with said carrier agent.
The losartan suspension formed has a significantly improved flavour and the bitter taste is significantly reduced. In addition, the suspension is substantially more stable than losartan solutions . It is to be noted that the term "suspension" used herein is where the losartan salt is substantially homogenously dispersed or "suspended" in the carrier agent. This is contrasted with prior art losartan "solutions" wherein the losartan salt is substantially dissolved in a carrier agent.
Any suitable salt of losartan can be used for the losartan suspension. Preferably the pharmaceutically acceptable salt of losartan used is losartan potassium.
Preferably the pH of the composition is less than 7.
Preferably the carrier agent is at a pH of less than 7. Alternatively, one or more pH modifying or buffering agents can be included in the composition with the carrier agent to adjust and/or maintain the pH below 7 and to an optimum pH value. The acidic pH of the final composition reduces the solubility of the losartan in the carrier agent, thereby forming the suspension.
The one or more pH modifying agents can include any or any combination of citric acid, sodium citrate, disodium hydrogen phosphate, sodium dihydrogen phosphate and/or the like. The pH modifying agents are used in such suitable amounts to provide the composition with an optimum pH. Preferably the one or more pH modifying agents are provided at a concentration of 7mmol. Further preferably the concentration of the one or more pH modifying agents is between 70-90mmol. Most preferably the concentration of the pH modifying agent is 90mmol.
Preferably the pH range of the final suspension is between 2-6, further preferably the pH range is 3.5-6 and yet further preferably the pH range is 3.5-4.5. In a preferred embodiment the pH of the final suspension is pH 4.0.
In one embodiment a wetting agent is included in the composition to aid dispersion of the losartan salt. This is preferable if the pH of the final suspension is 3 or below since at this pH the losartan salt can be difficult to disperse to form a substantially homogenous suspension.
Examples of possible wetting agents that can be used include a sorbiton fatty ester, such as for example Tween 80 (polysorbate 80) . Other surfactants or combinations of surfactants could also be used.
Preferably an anti-foaming agent is included in the composition to minimise the amount of foam produced during manufacture of the composition. The anti-foaming agent preferably includes a silicon based agent, such as for example simethicone emulsion
(Q7-2587 30%) .
In one embodiment one or more suspension agents are provided as the carrier agent or used in addition to the carrier agent. The suspension agent preferably acts to thicken the suspension to prevent settling of the losartan salt from the suspension. Preferably the one or more suspension agents include any or any combination of microcrystalline cellulose, carboxymethycellulose, carmellose sodium, Magnesium Aluminium Silicate (Veegum K), Xantham Gum, and/or any alternative salts thereof and/or the like.
Preferably where a combination of suspension agents is used which include Veegum K, the Veegum K is used in a larger amount than the other suspension agent or agents.
A combination of suspension agents is typically found to reduce the concentration of the agents required in the composition.
Preferred combinations include: a) Avicel RC591 (microcrystalline cellulose + carboxymethycellulose) with carmellose sodium; b) Veegum K with carboxymethycellulose sodium; or c) Veegum K with Xantham Gum.
In a preferred embodiment an optimum concentration of suspension agents include Veegum K at approximately 0.7%w/v combined with Xanthum Gum at approximately 0.4%w/v. (w/v —weight of the final volume of the composition) .
The combination and concentration of the suspension agents chosen typically provide a fluid or liquid pourable suspension which minimises the tendency of losartan to settle out of the suspension.
Preferably the carrier agent in one embodiment is an aqueous carrier agent, such as for example water or purified water.
Preferably one or more anti-microbial agents are included in the composition. For example sodium benzoate can be used at it is effective at the optimum pH of the composition. Alternatively the anti-microbrial agent could include any or any combination of benzoic acid, methyl hydroxybenzoate, propyl hydroxybenzoate, other analogues of the hydroxybenzoates and/or the like.
Preferably one or more sweetener agents, flavouring agents, anti-oxidant agents, preservative agents and/or the like are included in the composition.
Preferably a pharmaceutically acceptable dosage of the losartan salt is used in the composition. In a preferred embodiment the dosage is 50mg of losartan potassium in a 5ml aqueous solution.
According to a second aspect of the present invention there is provided a method of manufacturing a losartan composition suitable for oral administration, said method including the steps of mixing a pharmaceutically acceptable salt of losartan with a suitable carrier agent so that the losartan salt forms a suspension with the carrier agent.
Preferably the target pH of the composition is less than 7 and, if the composition is not less than 7 or unlikely to be less than 7, one or more pH modifiers are added to the composition before or after said losartan salt.
The composition can be mixed together using any suitable mixing means . In addition, the components of the composition can be mixed together in any order, although it is preferable that the pH modifiers or buffer components are added before the losartan salt to ensure the losartan remains as a suspension rather than a solution. If the losartan salt is added before the pH modifiers or buffers, it is likely that the losartan salt will dissolve into solution rather than forming a suspension. On subsequent addition of the pH modifiers or buffers, the losartan salt will precipitate out of the solution to form a suspension but the losartan salt may be of a different particle size.
Preferably the losartan salt is added to the composition in particulate or granular form. The particle size of the losartan potassium used to produce the composition is preferably between 14-150μm
The method of manufacture takes place at room temperature (i.e. approx 20-250C) and pressure (i.e. approx. 1 bar) .
According to a yet further aspect of the present invention there is provided use of a losartan suspension for the manufacture of a medicament for the treatment of lowering blood pressure in a patient. The patient is preferably a human patient.
Thus, the present invention provides a pharmaceutically effective, safe and simple to administer oral liquid dosage form that will benefit a patient group that have problems in swallowing.
A more detailed description of the present invention is provided below with reference to the accompanying figures and tables, wherein:
Figure 1 is a graph illustrating the stability of losartan in suspension at different pH values.
Example 1
Initial formulations for the losartan suspension were prepared at pH 2, 4 and 6 respectively using the formulation shown in Table 1 below:
Figure imgf000008_0001
Each suspension was given a batch number (D454-1/011A, D454-1/011B and D454-1/001C) and was stored in a suitable container at room temperature (250C). Samples were taken at 0, 2, 4, 8 and 12 weeks to determine the %SA (percentage of the stated amount of the single dose in the original sample of 50mg/5ml of losartan potassium). The results of the stability- test are shown in Figure 1 and Table 2 and Table 3 below:
Figure imgf000009_0001
Table 2
Figure imgf000009_0002
Table 3
The results show that the losartan suspension was stable at all pH's below 7 at room temperature and pressure and that the losartan salt was compatible with the other components contained in the composition. The optimum pH appeared to be pH 4.0.
The use of polysorbate 80 as a wetting agent aided the dispersion of the losartan salt in the formulation but was found not to be critical for forming the suspension. In addition, other wetting agents could be used if required. In order to determine the actual amount of the losartan salt present in the suspension, the following assay was undertaken using losartan potassium as the pharmaceutically acceptable salt.
Losartan potassium at a concentration of 1.0%w/v (5mg/ 5ml) was added to 90mmol of citrate phosphate buffer solutions at different pH and mixed until dispersed to form a suspension. The samples were then filtered and filtrate was analysed to determine the amount of losartan that had dissolved into solution. The amounts of losartan potassium in solution at the various pH's are shown in Table 4 below.
Figure imgf000010_0001
Table 4
It can be seen from the results in Table 4 that the solubility of losartan potassium was increased when the pH was higher. As such, an optimum suspension was found at pH 4 compared to suspensions with higher pH values. A pH of 4 appeared optimum since the amount of losartan dissolving into solution was minimised and the dispersion of the losartan potassium in the carrier agent is relatively easy. A lower pH would result in less losartan dissolving in the carrier agent but dispersion of the losartan would be more difficult.
Example 2
An example of a formulation for a losartan suspension is provided in Table 5 below.
Figure imgf000011_0001
Table 5
(PhEur- Pharmacopeia Europe) and (USP - United States
Pharmacopeia), QS — quantity sufficient.
In order to mask the bitter taste of losartan potassium sweeteners and flavourings in the form of liquid malititol, Acesulfame K and Compound Orange Spirit were used.
A detailed example of the method for making the formulation given in Table 5 is provided below:
1. Purified water (A) is added to the main manufacturing vessel. 2. The citric acid monohydrate is added to the main vessel and mixed until dissolved.
3. The sodium dihydrogen phosphate dihydrate is added to the main vessel and mixed until dissolved.
4. The sodium benzoate is added to the main vessel and mixed until dissolved.
5. The Tween 80 is added to the main vessel and mixed until dispersed.
6. The losartan potassium is added to the main vessel and mixed until a homogeneous suspension is produced.
7. The Simethicone emulsion (Q7-2587 30%) is added to the main vessel and mixed until dispersed.
8. The Veegum K and xanthan gum are added to a separate container and mixed until a uniform powder mixture is produced.
9. The powder blend produced at stage 8 is slowly added to the main vessel and mixed until dispersed and a homogeneous thickened suspension is produced.
10. The liquid maltitol is added to the main vessel and mixed until dispersed.
11. The Acesulfame k is added to the main vessel and mixed until dissolved.
12. The compound orange spirit is added to the main vessel and mixed until dispersed.
13. An in-process pH check is then carried out, (target pH is 4.0). If the pH is outside the range of 3.8 - 4.2 the pH is adjusted until it is within this range by adding either 10%w/w citric acid monohydrate solution to lower pH or 10%w/w solution of disodium hydrogen phosphate anhydrous to increase the pH.
14. Purified water (B) is then added to make to the final volume and mixed until dispersed.
15. The finished product is filled into amber glass bottles (to reduce any reaction with sunlight) which are closed with suitable closures.
A non-exhaustive selection of examples of alternative formulations which could be used for forming suspensions according to the present invention is provided in Tables 6-10 below.
Table 6 (suspension at pH 3, without wetting agent, pH modifier is Citric acid )
Inqredient Quantity Required
Purified water 500.Og
Citric Acid Monohydrate 15.Og
Sodium Benzoate 1.2g
Losartan Potassium 10.0g
Magnesium Aluminium silicate (Veegum K) 7.Og
Xanthan Gum 3.0g
Simethicone Emulsion (Q7-2587-30%) 0.5g
Liquid Maltitol (Hydrogenated Glucose Syrup) 400.Og
Acesulfame K 1.0g
Purified water (to final volume) To IOOOmI Table 7 (pH 4, without wetting agent, pH Buffer system is Citric acid/ Sodium Dihydrogen phosphate)
Quantity
Inqredient Reαuired
Purified water 500.Og
Citric Acid Monohydrate 5.5g
Sodium Dihydrogen phosphate 10.0g
Sodium Benzoate 1.2g
Losartan Potassium 10.0g
Magnesium Aluminium silicate (Veegum K) 7.Og
Xanthan Gum 3.Og
Simethicone Emulsion (Q7-2587-30%) 0.5g
Liquid Maltitol (Hydrogenated Glucose Syrup) 400.Og
Acesulfame K 1.0g
Purified water (to final volume) To IOOOmI
Table 8 ( pH 3 with 0.1% polysorbate 80 as wetting agent, pH modifier is Citric acid)
Quantity
Inqredient Required
Purified water 500.0g
Citric Acid Monohydrate 15.Og
Sodium Benzoate 1.2g
Polysorbate 80 (Tween 80) 1.0g
Losartan Potassium 10.0g
Magnesium Aluminium silicate (Veegum K) 7.Og
Xanthan Gum 3.Og
Simethicone Emulsion (Q7-2587-30%) 0.5g
Liquid Maltitol (Hydrogenated Glucose Syrup) 400.0g
Acesulfame K 1.0g
Purified water (to final volume) To 1000ml Table 9 (pH 4 without wetting agent but with Xanthan gum increased from 0.3% to 0.4%) i j- i. Quantity
Purified water 500.Og
Citric Acid Monohydrate 15.Og
Sodium Dihydrogen Phosphate Dihydrate 10.0g
Sodium Benzoate 1.2g
Losartan Potassium 10.0g
Magnesium Aluminium silicate (Veegum K) 7.Og
Xanthan Gum 4.Og
Simethicone Emulsion (Q7-2587-30%) 0.5g
Liquid Maltitol (Hydrogenated Glucose Syrup) 400.Og
Acesulfame K 1.Og
Purified water (to final volume) To 1000ml
Table 10 (pH 4 with 0.1% polysorbate 80, and 0.4% Xanthan gum)
Inqredient Quantity Required
Purified water 500.Og
Citric Acid Monohydrate 15.Og
Sodium Dihydrogen Phosphate Dihydrate 10.0g
Sodium Benzoate 1.2g
Polysorbate 80 (Tween 80) 1.0g
Losartan Potassium 10.0g
Magnesium Aluminium silicate (Veegum K) 7.Og
Xanthan Gum 3.Og
Simethicone Emulsion (Q7-2587-30%) 0.5g
Liquid Maltitol (Hydrogenated Glucose Syrup) 400.Og
Acesulfame K LOg
Purified water (to final volume) To I OOOmI

Claims

Claims:
1. A losartan composition suitable for oral administration, said composition containing a pharmaceutically acceptable salt of losartan and a carrier agent, the losartan salt forming a suspension with said carrier agent.
2. A losartan composition according to claim 1 wherein the pH of said composition is less than 7.
3. A losartan composition according to claim 1 wherein the pH of the composition is between 2-6.
4. A losartan composition according to claim 1 wherein the pH of the composition is between 3.5-6.0.
5. A losartan composition according to claim 1 wherein the pH of the composition is between 3.5-4.5.
6. A losartan composition according to claim 1 wherein the pH of the composition is pH 4.0.
7. A losartan composition according to claim 1 wherein the pharmaceutically acceptable salt of losartan is losartan potassium.
8. A losartan composition according to claim 1 wherein the carrier agent is at a pH of less than 7 prior to mixing with the losartan salt.
9. A losartan composition according to claim 1 wherein the composition includes one or more pH modifying or buffering agents to adjust and/or maintain the pH of the composition below 7.
10. A losartan composition according to claim 9 wherein the one or more pH modifying or buffering agents include any or any combination of citric acid, sodium citrate, disodium hydrogen phosphate or sodium dihydrogen phosphate.
1 1. A losartan composition according to claim 9 wherein the one or more pH modifying agents are provided at a concentration of 7mmol.
12. A losartan composition according to claim 9 wherein the one or more pH modifying agents are provided at a concentration of between 70-90mmol.
13. A losartan composition according to claim 9 wherein the one or more pH modifying agents are provided at a concentration of 90mmol.
14. A losartan composition according to claim 1 wherein a wetting agent is included in the composition.
15. A losartan composition according to claim 14 wherein the wetting agent is used if the pH of the composition is 3 or below.
16. A losartan composition according to claim 14 wherein the wetting agent is a sorbiton fatty ester.
17. A losartan composition according to claim 16 wherein the wetting agent is polysorbate 80 or Tween 80.
18. A losartan composition according to claim 1 wherein an anti-foaming agent is included in the composition.
19. A losartan composition according to claim 18 wherein the anti-foaming agent includes a silicon based agent.
20. A losartan composition according to claim 19 wherein the silicon based agent is simethicone emulsion.
21. A losartan composition according to claim 1 wherein one or more suspension agents are included in the composition in addition to the carrier agent.
22. A losartan composition according to claim 21 wherein the one or more suspension agents include any or any combination of microcrystalline cellulose, carboxymethylcellulose, carmellose sodium, magnesium aluminium silicate (veegum K), xanthum gum and/ or any alternative salts thereof.
23. A losartan composition according to claim 22 wherein when a combination of suspension agents is used which include veegum K, said veegum K is used in a larger amount than the other suspension agent or agents.
24. A losartan composition according to claim 21 wherein combinations of suspension agents are used and said combinations include any of microcrystalline cellulose, carboxymethylcellulose and carmellose sodium; veegum K and carboxymethylcellulose sodium; or veegum K and xanthum gum.
25. A losartan composition according to claim 24 wherein a combination of suspension agents including approximately 0.7% w/v of veegum K combined with approximately 0.4% w/v of xanthum gum.
26. A losartan composition according to claim 1 wherein the carrier agent is an aqueous carrier agent.
27. A losartan composition according to claim 1 wherein one or more anti-microbial agents are included in the composition.
28. A losartan composition according to claim 27 wherein the one or more anti-microbial agents include any or any combination of sodium benzoate, benzoic acid, methyl Hydroxybenzoate, propyl Hydroxybenzoate and/or other analogues of Hydroxybenzoate.
29. A losartan composition according to claim 1 wherein one or more sweetener agents, flavouring agents, antioxidant agents and/or preservative agents are included in the composition.
30. A losartan composition according to claim 29 wherein the one or more sweetener agents include liquid maltitol and/ or Acesulfame K.
31. A losartan composition according to claim 29 wherein the one or more flavouring agents include compound orange spirit.
32. A losartan composition according to claim 1 wherein the pharmaceutically acceptable dosage of the losartan salt is 50mg of losartan potassium in a 5ml aqueous solution.
33. A method of manufacturing a losartan composition suitable for oral administration, said method including the steps of mixing a pharmaceutically acceptable salt of losartan with a suitable earner agent so that the losartan salt forms a suspension with the carrier agent.
34. A method according to claim 33 wherein one or more pH modifying agents are added to the carrier agent prior to addition of the losartan salt.
35. A method according to claim 33 wherein the pharmaceutically acceptable salt of losartan is added to the composition in particulate or granular form.
36. A method according to claim 35 wherein particle size of the losartan salt is 14-150μm.
37. Use of a losartan suspension for the manufacture of a medicament for the treatment of lowering blood pressure in a patient.
PCT/GB2009/000531 2008-03-12 2009-02-25 Losartan composition WO2009112800A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0804536.1 2008-03-12
GBGB0804536.1A GB0804536D0 (en) 2008-03-12 2008-03-12 Losartan composition

Publications (1)

Publication Number Publication Date
WO2009112800A1 true WO2009112800A1 (en) 2009-09-17

Family

ID=39327938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/000531 WO2009112800A1 (en) 2008-03-12 2009-02-25 Losartan composition

Country Status (2)

Country Link
GB (1) GB0804536D0 (en)
WO (1) WO2009112800A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557944A1 (en) * 2010-04-15 2013-02-20 Chromocell Corporation Compounds, compositions, and methods for reducing or eliminating bitter taste
US9706790B2 (en) 2011-10-20 2017-07-18 Chromocell Corporation Compounds, compositions, and methods for reducing or eliminating bitter taste
WO2020039262A1 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceuticals solution for oral dosage
US11890273B2 (en) 2020-10-09 2024-02-06 Scienture, Inc. Losartan liquid formulations and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026026A1 (en) * 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026026A1 (en) * 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MERCK & CO., INC: "COZAAR: Losartan Potassium Tablets", INTERNET ARTICLE, December 2005 (2005-12-01), pages 3 - 18, XP002529970, Retrieved from the Internet <URL:http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020386s045lbl.pdf> [retrieved on 20090610] *
SEBURG ET AL: "Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 42, no. 4, 11 October 2006 (2006-10-11), NEW YORK, NY, US, pages 411 - 422, XP005657182, ISSN: 0731-7085 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557944A1 (en) * 2010-04-15 2013-02-20 Chromocell Corporation Compounds, compositions, and methods for reducing or eliminating bitter taste
EP2557944A4 (en) * 2010-04-15 2014-06-11 Chromocell Corp Compounds, compositions, and methods for reducing or eliminating bitter taste
US8865779B2 (en) 2010-04-15 2014-10-21 Chromocell Corporation Compounds, compositions, and methods for reducing or eliminating bitter taste
US9408407B2 (en) 2010-04-15 2016-08-09 Chromocell Corporation Compounds, compositions, and methods for reducing or eliminating bitter taste
US9872514B2 (en) 2010-04-15 2018-01-23 Chromocell Corporation Compounds, compositions, and methods for reducing or eliminating bitter taste
US9706790B2 (en) 2011-10-20 2017-07-18 Chromocell Corporation Compounds, compositions, and methods for reducing or eliminating bitter taste
WO2020039262A1 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceuticals solution for oral dosage
GB2591389A (en) * 2018-08-18 2021-07-28 Ftf Pharma Private Ltd Pharmaceuticals solution for oral dosage
US11738020B2 (en) 2018-08-18 2023-08-29 Ftf Pharma Private Limited Stable liquid vigabatrin pharmaceutical composition for oral dosage
US12016857B2 (en) 2018-08-18 2024-06-25 Ftf Pharma Private Limited Stable liquid vigabatrin pharmaceutical composition for oral dosage
US11890273B2 (en) 2020-10-09 2024-02-06 Scienture, Inc. Losartan liquid formulations and methods of use
US12156869B2 (en) 2020-10-09 2024-12-03 Scienture, Inc. Losartan liquid formulations and methods of use

Also Published As

Publication number Publication date
GB0804536D0 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
EP2395979B1 (en) Delayed release, oral dosage compositions that contain amorphous cddo-me
CA2567075C (en) Pharmaceutical suspension composition
AU2008320458B2 (en) Stabilized pediatric suspension of carisbamate
CN100337630C (en) Palatable oral suspensions and methods of making same
EP0524579B1 (en) Improved oral dosing formulations of dideoxy purine nucleosides
EP2377538A1 (en) Aqueous oral preparation of stable amlodipine
US20020028794A1 (en) Megestrol acetate suspension
EP1858494B1 (en) New soft gelatin capsules
JP2021523202A (en) Oral solution preparation
WO2009112800A1 (en) Losartan composition
JP2013241422A (en) Stable aqueous suspension preparation
JP2012526856A (en) Oral suspension containing telmisartan
WO2012013117A1 (en) Pharmaceutical composition of temozolomide comprising vitamin c or vitamin c derivative and preparation method thereof
KR20140081738A (en) Pharmaceutical composition in the form of an oral suspension comprising flavonoid fraction and xanthan gum
WO2020212898A1 (en) Pharmaceutical oral liquid solution of ivacaftor
WO2019075127A1 (en) Midodrine hydrochloride oral solution and uses thereof
WO2005007168A1 (en) A stable clozapine suspension formulation
CA2417258A1 (en) Flavoring systems for pharmaceutical compositions and methods of making such compositions
WO2015137829A1 (en) Stable and palatable liquid pharmaceutical composition of phenylephrine and a maleate salt of an antihistamine
JP2006527726A (en) Pharmaceutical formulation containing amoxicillin and clavulanate
RU2770041C2 (en) Furazidin composition in the form of a suspension and a method for its preparation
KR20200083971A (en) Calcium supplement composition
TWI619716B (en) Pharmaceutical composition of temozolomide comprising vitamin c or its derivatives and preparation method thereof
GB2564515A (en) Pharmaceutical composition and a method for manufacturing the same
WO2009127802A1 (en) Rosiglitazone composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09718757

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09718757

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载